Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BsUFA III: Reauthorization Process Begins With US FDA Considering Staffing, Uptake Issues

Nov 18 2020

• By Derrick Gingery

FDA entrance sign 2016 — The virtual BsUFA III kick-off meeting is scheduled for 9 a.m. to 12:30 p.m. on 19 November.

Related Content

Sandoz Sees Revolution In US Biosimilars Market

Sep 25 2020

US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs

Jun 07 2018

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

Nov 18 2020

Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced

Jun 23 2020

BsUFA III: Could Regulatory Science Research Emerge With Other Tweaks?

Feb 04 2020

US FDA Personnel Costs Drop: Is The Next Generation Taking Over?

Sep 08 2020

FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office

Sep 11 2019

Biosimilar Sponsors Want Off-The-Record Labeling Discussions With US FDA

Dec 10 2019

US FDA Drug Review Hiring Doing Well Despite Pandemic

Oct 26 2020

Related Companies

Sandoz Inc.

Amgen, Inc.

Additional Topics

United States Biosimilars User Fees Regulation FDA Post Market Regulation & Studies BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window